Inovio Pharmaceuticals (INO) Q3 2024 earnings summary

Executive summary

• INO-3107 advanced toward commercialization for RRP, with 81% of Phase 1/2 patients experiencing reduced surgeries and new immunology data supporting its mechanism; BLA submission targeted for mid-2025, with all non-device modules on track for completion by year-end 2024.

• Manufacturing issue with the device component identified, with resolution underway and not expected to delay the BLA timeline; collaborations continue for other indications and geographies.

• No treatment-related adverse events above Grade 2 reported in INO-3107 Phase 1/2 trial; full safety and efficacy data presented at major conferences.

• Pipeline progress includes regulatory alignment for INO-3112 Phase III trial, ongoing studies for INO-5401 and INO-4201, and early-stage DNA-encoded monoclonal antibody data expected by year-end.

• Commitment to financial discipline, reducing operating expenses, and maintaining a strong cash position.

Financial highlights

• Q3 2024 operating expenses decreased 24% year-over-year to $27.3 million, with R&D expenses at $18.7 million and G&A at $8.6 million.

• Net loss for Q3 2024 was $25.2 million ($0.89 per share), improved from $33.9 million ($1.52 per share) in Q3 2023.

• Cash, cash equivalents, and short-term investments totaled $84.8 million as of September 30, 2024, with working capital of $67.8 million.

• Cash runway projected into Q3 2025, with estimated Q4 2024 net cash burn of $24 million; projections exclude potential capital-raising activities.

• No debt on the balance sheet; accumulated deficit reached $1.7 billion as of September 30, 2024.

Outlook and guidance

• BLA submission for INO-3107 planned for mid-2025, with launch readiness targeted by end of 2025 and long-term clinical durability data expected by year-end 2024.

• Confirmatory trial for INO-3107 to commence before BLA submission, with most sites identified and contracting underway.

• Cash position expected to support operations into Q3 2025, excluding new capital raises; additional financing will be required beyond that point.

• Commercial build-out and field teams planned for 2025, with a lean and efficient approach.

• Ongoing evaluation of collaborations and capital raising to fund operations and development pipeline.